

FluoGuide appoints Jens Ellrich as Chief Medical Officer

Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a biotech company specializing in precision cancer surgery, announces the appointment of Jens Ellrich as Chief Medical Officer, effective November 1, 2024.

Jens Ellrich, a German physician and medical scientist, brings over 30 years of extensive experience in translational neuroscience, medical devices, biotechnology, pharmacology, and digital therapeutics. His proven track record spans both academia and the start-up ecosystem, where he has successfully advanced innovative medical solutions across drugs, devices, and their combinations. Jens Ellrich has played a key role in the development and launch of groundbreaking therapies at international companies such as the start-up Sapiens Steering Brain Stimulation acquired by Medtronic.

At FluoGuide, Jens Ellrich will lead the execution of late-stage clinical trials and spearhead the preparation for commercialization of the company’s lead product, FG001. This technology has shown significant promise in illuminating cancerous tissues, enhancing the precision and effectiveness of surgeries for aggressive brain cancers, head and neck cancers (oropharyngeal squamous cell carcinoma), and lung cancer (non-small cell lung cancer).

Jens Ellrich will succeed Co-Founder and Chief Scientific Officer Andreas Kjaer in the role of Chief Medical Officer, a position Andreas Kjaer has also been overseeing since 2020.

“We are thrilled to welcome Jens to our team. His extensive experience in the biotech industry, particularly in advancing innovative therapies from concept to market, makes him an invaluable addition to FluoGuide. Jens’ expertise will be instrumental as we move into the critical phase of late-stage clinical trials and prepare for the commercialization of FG001 and will help ensure that our technology reaches its full potential in improving surgical outcomes for patients with cancers” says CEO Morten Albrechtsen.

The appointment of Jens Ellrich follows the recent addition of two new board members, Donna Haire and Roger Gunnarsson to strengthen FluoGuide's organization as it advances late-stage clinical trials and prepares for the commercialization of its lead product, FG001. Donna Haire brings extensive expertise across regulatory and clinical affairs, operations, and R&D, while Roger Gunnarsson is a leading financial and M&A advisor with a global network in healthcare.

For further information, please contact:

Morten Albrechtsen, CEO
FluoGuide A/S
+45 24 25 62 66,
ma@fluoguide.com

Certified Adviser:

Svensk Kapitalmarknadsgranskning AB

About FluoGuide

FluoGuide is a biotech company specializing in precision cancer surgery. FluoGuide's lead product, FG001, is designed to enhance surgical accuracy by illuminating cancer cells intraoperatively using fluorescent light, which binds to the uPAR receptor, widely expressed in most solid cancer types. It is anticipated that FG001 will decrease both the incidence of local recurrence after surgery and surgical complications, improving cancer treatment and outcomes for patients, while also reducing healthcare costs. Moreover, FluoGuide's technology platform may also be utilized for photothermal therapy (PTT), which kills cancer cells through heating them with the use of near-infrared light. A technique that spares healthy surrounding tissue from damage, offering a direct therapeutic effect of FG001, further benefiting patients undergoing cancer surgery.

FluoGuide is listed on the Nasdaq First North Growth Market in Stockholm under the ticker symbol "FLUO." For more information about FluoGuide's pipeline, technology, and upcoming events, visit www.fluoguide.com.

Attachments

[FluoGuide appoints Jens Ellrich as Chief Medical Officer](#)